Temporal effect of neoadjuvant androgen deprivation therapy on PSA kinetics following permanent prostate brachytherapy with or without supplemental external beam radiation

Brachytherapy

Volumn 3, Issue 3, 2004, Pages 141-146

  Merrick, Gregory S ^a,b   Butler, Wayne M ^a,b   Wallner, Kent E ^c,d,e   Galbreath, Robert W ^a   Allen, Zachariah ^a   Adamovich, Edward ^f  

^a WHEELING HOSPITAL   (United States)

^b WHEELING HOSPITAL   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e CENTER FOR HEALTH STUDIES   (United States)

^f WHEELING JESUIT UNIVERSITY   (United States)

Author keywords

Androgen deprivation therapy; Brachytherapy; Prostate; PSA kinetics

Indexed keywords

IODINE 125; LEAD; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADJUVANT THERAPY; ADULT; AGED; ANDROGEN THERAPY; ARTICLE; BIOCHEMISTRY; BRACHYTHERAPY; CANCER SURVIVAL; COMPARATIVE STUDY; FOLLOW UP; HUMAN; KINETICS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL SIGNIFICANCE; TIME SERIES ANALYSIS;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 8144228070     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2004.07.002     Document Type: Article

References (24)

1. G.S. Merrick, K.E. Wallner, and W.M. Butler Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland J Urol 169 2003 1643 1652
2. G.S. Merrick, K.E. Wallner, and W.M. Butler Minimizing prostate brachytherapy-related morbidity Urology 62 2003 786 792
3. G.S. Merrick, W.M. Butler, and R.W. Galbreath Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer? BJU Int 91 2003 23 29
4. L.N. Lee, R.G. Stock, and N.N. Stone Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation Int J Radiat Oncol Biol Phys 52 2002 444 452
5. A. Hinerman-Mulroy, G.S. Merrick, and W.M. Butler Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity following permanent interstitial brachytherapy Int J Radiat Oncol Biol Phys 59 2004 1367 1382
6. L. Potters, T. Torre, and R. Ashley Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy J Clin Oncol 18 2000 1187 1192
7. R. Kucway, F. Vicini, and R. Huang Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy J Urol 167 2002 2443 2447
8. G.S. Merrick The role of hormonal therapy in prostate brachytherapy Brachytherapy 2 2003 2 4
9. W.R. Lee, J. Moughan, and J.B. Owen The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: A comprehensive survey of prostate brachytherapy in the United States Cancer 98 2003 1987 1994
10. G.S. Merrick, W.M. Butler, and K.E. Wallner Prostate-specific antigen spikes after permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 54 2002 450 456
11. G.S. Merrick, W.M. Butler, and K.E. Wallner Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy Brachytherapy 2 2003 181 188
12. M.K. Buyyounouski, A.L. Hanlon, and A. Pollack The temporal kinetics of PSA after 3D-conformal radiotherapy with androgen deprivation Int J Radiat Oncol Biol Phys 57 Suppl. 2 2003 147
13. M.E. Gleave, S.L. Goldenberg, and J.L. Chin Randomized comparative study of 3- versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathologic effects J Urol 166 2001 500 507
14. A. Hurtado-Coll, S.L. Goldenberg, and L. Klotz Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: The Canadian experience Urology 60 Suppl. 3A 2002 45 51
15. G.D.A. Padula, M.J. Zelefsky, and E.S. Venkatraman Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 52 2002 439 443
16. M.G. Oefelein Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: Implications for dosing schedule and neoadjuvant study consideration J Urol 160 1998 1685 1688
17. J.M. Crook, E. Szumacher, and S. Malone Intermittent androgen suppression in the management of prostate cancer Urology 53 1999 530 534
18. R.J. Negat, H.H. Rashid, and E. Bagiella A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy J Urol 164 2000 1891 1894
19. American Society for Therapeutic Radiology and Oncology Consensus Panel Consensus Statement: Guidelines for PSA following radiation therapy Int J Radiat Oncol Biol Phys 37 1997 1035 1041
20. H. Thames, D. Kuban, and L. Levy Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995 Int J Radiat Oncol Biol Phys 57 2003 929 943
21. G.S. Merrick, W.M. Butler, and W.H. Farthing The impact of Gleason score accuracy as a criterion for prostate brachytherapy patient selection J Brachytherapy Int 14 1998 112 121
22. R. Nath, L.L. Anderson, and G. Luxton Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 Med Phys 22 1995 209 234
23. G.S. Merrick, and W.M. Butler Modified uniform seed loading for prostate brachytherapy: Rationale, design, and evaluation Tech Urol 6 2000 78 84
24. G.S. Merrick, W.M. Butler, and A.T. Dorsey Seed fixity in the prostate/periprostatic region following brachytherapy Int J Radiat Oncol Biol Phys 46 2000 215 220